Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 15/20 | 0.55 |
| ▸ | CDK2 | P24941 | 15/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.55 |
| ▸ | CDK4 | P11802 | 4/20 | 0.55 |
| ▸ | CCND3 | P30281 | 4/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | AURKA | O14965 | 4/20 | 0.40 |
| ▸ | PLK1 | P53350 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11022675 | 0.88 | CCNA2 (0.68) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL10216355 | 0.88 | CCNA2 (0.52) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL9940940 | 0.85 | CCNA2 (0.51) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL9940904 | 0.85 | CCNA2 (0.48) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3505467 | 0.78 | CCNA2 (0.57) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL1559142 | 0.78 | CDK2 (0.57) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4162140 | 0.78 | CCNA2 (0.67) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4154590 | 0.77 | CCNA2 (0.66) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL1559207 | 0.77 | CCNA2 (0.66) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL1559150 | 0.77 | CCNA2 (0.66) | CCNA2CDK2CCNA1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CCNA2 1765/4885CDK2 113/4885CCNA1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.